SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19
- Sci Transl Med. 2021 Apr 21;13(590):eabf7872. doi: 10.1126/scitranslmed.abf7872.
- 1. Gladstone Institutes, San Francisco, CA 94158, USA.
- 2. Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.
- 3. UC Berkeley-UCSF Joint Program in Bioengineering, Berkeley, CA 94720, USA.
- 4. Department of Neurology, UCSF, San Francisco, CA 94143, USA.
- 5. Department of Laboratory Medicine, UCSF, San Francisco, CA 94143, USA.
- 6. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.
- 7. Gladstone Institutes, San Francisco, CA 94158, USA. [email protected] [email protected] [email protected].
- 8. Department of Medicine, UCSF, San Francisco, CA 94143, USA.
- 9. Innovative Genomics Institute, Berkeley, CA 94704, USA.
- 10. Department of Ophthalmology, UCSF, San Francisco, CA 94158, USA.
- 11. Department of Bioengineering and Therapeutic Sciences, UCSF, San Francisco, CA 94158, USA.
Although coronavirus disease 2019 (COVID-19) causes cardiac dysfunction in up to 25% of patients, its pathogenesis remains unclear. Exposure of human induced pluripotent stem cell (iPSC)-derived heart cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed productive Infection and robust transcriptomic and morphological signatures of damage, particularly in cardiomyocytes. Transcriptomic disruption of structural genes corroborates adverse morphologic features, which included a distinct pattern of myofibrillar fragmentation and nuclear disruption. Human autopsy specimens from patients with COVID-19 reflected similar alterations, particularly sarcomeric fragmentation. These notable cytopathic features in cardiomyocytes provide insights into SARS-CoV-2-induced cardiac damage, offer a platform for discovery of potential therapeutics, and raise concerns about the long-term consequences of COVID-19 in asymptomatic and severe cases.
-
Cat. No.Product NameDescriptionTargetResearch Area
-